Overview
The discipline of pharmacovigilance has undergone immense transformation throughout the world, in the last decade than ever before. With more regulatory actions being pronounced and with many countries enacting pharmacovigilance legislations, it is being increasingly recognized that patient safety is a concern for not only the regulators but other stakeholders too. Application and adoption of appropriate technology coupled with the exponential growth in the science of pharmacovigilance is revolutionizing patient safety in real time. Developing innovative workflows and deployment of relevant automation in carrying out pharmacovigilance activities indicates that the era of Electronic Pharmacovigilance has already arrived and is here to stay. Today, India holds a unique position in the pharmacovigilance space as the most preferred destination for global pharmaceutical companies to outsource their drug safety activities. In parallel, India is also firming up the country’s regulatory system to ensure utmost safety in clinical trials as well as in the post-marketing stages, which is a significant step into a promising future.
This conference aspires to bring together thought leaders representing many of the stakeholders of pharmacovigilance to deliberate the current best practices, debate on the available technology tools for data mining, elucidate on novel initiatives to augment handling of drug safety data and many other niche topics, with the focus being on pharmacovigilance and related professionals in India. The two-day conference will ensure enough opportunity to interact with speakers and colleagues from the entire spectrum of the pharmacovigilance domain in India.”
Learning objectives
At the end of this conference, the participants should be able to:
- Comprehend multiple facets of global drug safety concepts along with insights on Indian pharmacovigilance
- Understand how new technologies can help in improving adverse event reporting and processing of safety data
- Discuss the advancements in pharmacovigilance in the European Union and how it influences the global drug safety
- Brainstorm on special interests like pharmacovigilance of vaccines, biologics, medical devices & alternative medicines
Program Committee
-
Moin Don • CEO and President
PVCON Pharmacovigilance Consulting Services, India -
Vivek Ahuja, DrMed • Vice President, Global Pharmacovigilance
ArisGlobal, United States -
Arun D. Bhatt, MD • Consultant Clinical Research & Development
Consultant, India -
Chitra Lele, PhD • Chief Scientific Officer
Sciformix Technologies Pvt. Ltd., India -
Himanshu Verma • Cofounder & CEO
ConsilX, India -
Shravanti Bhowmik, MD • VP - Clinical Operations
Sun Pharmaceuticals Advanced Research Co., Ltd., India -
Sibin Kurian • Therapeutic Area Safety Lead
Novartis Pharma AG,, Switzerland -
Anish Desai • Medical Director - Medical Devices
Johnson & Johnson Medical India, India -
J Vijay Venkatraman, MD, MBA • Managing Director and CEO
Oviya MedSafe, India -
Jamal Anwar Baig, PhD • Country Head- Pharmacovigilance
Merck Sharp & Dohme, India -
Mangesh Kulkarni, MD • Head Drug Safety
Tata Consultancy Services, India -
Manoj Swaminathan • Chief Manager / Head Global Pharmacovigilance Center
Piramal Enterprises Ltd, India -
Milind Sardesai • GM - Medical Safety Services
Cognizant Technology Solutions India, India -
Retesh Kumar • Senior Business Consultant & Engagement Lead
Tata Consultancy Services , India
